Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

IPSC

Century Therapeutics Inc

Sep 20 • 04:00PM ET

1.70

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN SCHA VTWO IWC VHT SCHB VTWV

Index	RUT	P/E	-	EPS (ttm)	-2.04	Insider Own	61.59%	Shs Outstand	60.34M	Perf Week	6.25%
Market Cap	144.02M	Forward P/E	-	EPS next Y	-1.86	Insider Trans	-0.05%	Shs Float	32.54M	Perf Month	-5.03%
Income	-131.39M	PEG	-	EPS next Q	-0.45	Inst Own	26.49%	Short Float	8.69%	Perf Quarter	-40.56%
Sales	2.04M	P/S	70.60	EPS this Y	23.46%	Inst Trans	-1.45%	Short Ratio	8.05	Perf Half Y	-64.44%
Book/sh	2.63	P/B	0.65	EPS next Y	-5.56%	ROA	-31.52%	Short Interest	2.83M	Perf Year	-24.11%
Cash/sh	2.32	P/C	0.73	EPS next 5Y	-	ROE	-55.95%	52W Range	1.28 - 5.51	Perf YTD	-48.80%
Dividend Est.	-	P/FCF	-	EPS past 5Y	15.24%	ROI	-47.81%	52W High	-69.15%	Beta	1.37
Dividend TTM	-	Quick Ratio	10.62	Sales past 5Y	-14.25%	Gross Margin	-488.98%	52W Low	32.81%	ATR (14)	0.17
Dividend Ex-Date	-	Current Ratio	10.62	EPS Y/Y TTM	5.99%	Oper. Margin	-6321.69%	RSI (14)	49.12	Volatility	8.98% 9.96%
Employees	165	Debt/Eq	0.25	Sales Y/Y TTM	-55.26%	Profit Margin	-6434.23%	Recom	1.33	Target Price	9.00
Option/Short	Yes / Yes	LT Debt/Eq	0.24	EPS Q/Q	32.34%	Payout	-	Rel Volume	1.92	Prev Close	1.70
Sales Surprise	79.30%	EPS Surprise	16.45%	Sales Q/Q	678.79%	Earnings	Aug 08 BMO	Avg Volume	351.29K	Price	1.70
SMA20	2.75%	SMA50	-13.32%	SMA200	-45.09%	Trades		Volume	675,785	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-08-24	Initiated	Rodman & Renshaw	Buy	$6
Aug-28-23	Downgrade	JP Morgan	Overweight → Neutral	$28 → $5
Dec-27-22	Initiated	Chardan Capital Markets	Buy	$19
Oct-31-22	Initiated	Guggenheim	Buy	$15
Oct-10-22	Initiated	Canaccord Genuity	Buy	$28
May-23-22	Initiated	H.C. Wainwright	Buy	$27
May-12-22	Initiated	William Blair	Mkt Perform
Jul-13-21	Initiated	Piper Sandler	Overweight	$38
Jul-13-21	Initiated	JP Morgan	Overweight	$40
Jul-13-21	Initiated	BofA Securities	Buy	$34

Aug-08-24 08:50AM	Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-09-24 12:00PM	Century Therapeutics (IPSC) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Jun-03-24 07:00AM	Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting (GlobeNewswire)
May-10-24 03:35PM	Century Therapeutics Inc (IPSC) Q1 2024 Earnings: Aligns with EPS Projections Amid Strategic ... (GuruFocus.com)
07:00AM	Loading…
07:00AM	Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting (GlobeNewswire)
May-09-24 01:54PM	IPSC Stock Earnings: Century Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:40AM	Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-23-24 07:00AM	Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit (GlobeNewswire)
Apr-11-24 08:25AM	Century buys a startup, raises funding in cell therapy expansion (BioPharma Dive) +7.14%
07:00AM	Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics (GlobeNewswire)
Apr-08-24 04:05PM	Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +6.08%
Mar-25-24 07:00AM	Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors (GlobeNewswire) -9.48%
Mar-19-24 07:00AM	Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference (GlobeNewswire)
01:52PM	Loading…
Mar-14-24 01:52PM	IPSC Stock Earnings: Century Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -7.20%
07:30AM	Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-08-24 11:55PM	Century Therapeutics Inc (IPSC) COO Adrienne Farid Sells 53,515 Shares (GuruFocus.com)
Mar-07-24 09:55AM	How Much Upside is Left in Century Therapeutics, Inc. (IPSC)? Wall Street Analysts Think 193.4% (Zacks) +6.30%
Mar-05-24 06:03PM	Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +17.65%
Feb-01-24 07:00AM	Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Dec-09-23 12:00PM	Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion Edits (GlobeNewswire)
Dec-07-23 11:01AM	Century (IPSC) Up 36% on FDA Nod to Begin Phase I Lupus Study (Zacks) +8.37%
Dec-06-23 07:30AM	Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus (GlobeNewswire) +36.08%
07:30AM	Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus (GlobeNewswire)
Dec-05-23 08:55AM	Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger Potential (InvestorPlace)
Nov-21-23 07:00AM	Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-14-23 03:58PM	FMR LLC Adjusts Position in Century Therapeutics Inc (GuruFocus.com)
Nov-09-23 08:29AM	Century Therapeutics Inc (IPSC) Reports Q3 2023 Financial Results (GuruFocus.com) -13.13%
07:01AM	Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
07:00AM	Loading…
07:00AM	Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer (GlobeNewswire)
07:00AM	Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases (GlobeNewswire)
Nov-02-23 09:00AM	Century Therapeutics to Present Initial Clinical Data Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion Edits at the 65th ASH Annual Meeting and Exposition (GlobeNewswire)
Sep-26-23 07:00AM	Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference (GlobeNewswire)
Aug-09-23 08:50AM	Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-01-23 06:48AM	Century Therapeutics (NASDAQ:IPSC) shareholders have endured a 71% loss from investing in the stock a year ago (Simply Wall St.)
May-12-23 06:11AM	Century Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
May-11-23 08:55AM	Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-17-23 07:00AM	Century Therapeutics to Present at Chardans 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit (GlobeNewswire)
Apr-12-23 08:30AM	Century Therapeutics Announces Leadership Changes (GlobeNewswire) -7.91%
Mar-16-23 08:55AM	Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-15-23 04:01PM	Century Therapeutics to Present at the AACR Annual Meeting 2023 (GlobeNewswire)
Feb-21-23 07:00AM	Century Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-08-23 07:30AM	Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas (GlobeNewswire)
Feb-01-23 07:00AM	Century Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-17-23 09:35AM	After Plunging -29.84% in 4 Weeks, Here's Why the Trend Might Reverse for Century Therapeutics, Inc. (IPSC) (Zacks) -7.36%
Jan-09-23 10:46AM	Century Therapeutics becomes latest life sciences company to enact layoffs, narrow focus (American City Business Journals)
Jan-06-23 08:23AM	Century Therapeutics Announces Internal Portfolio Prioritization, Analyst Views It As Incrementally Positive (Benzinga)
Jan-05-23 04:01PM	Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026 (GlobeNewswire)
Jan-04-23 07:00AM	Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-08-22 10:02AM	Further weakness as Century Therapeutics (NASDAQ:IPSC) drops 12% this week, taking one-year losses to 39% (Simply Wall St.)
Nov-22-22 07:00AM	Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire) +5.24%
Nov-11-22 07:00AM	Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates (GlobeNewswire) -5.01%
Nov-10-22 08:45AM	Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +15.11%
07:30AM	Century Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-02-22 07:05AM	Century Therapeutics to Host Virtual Research and Development Day on November 11, 2022 (GlobeNewswire)
Oct-05-22 04:05PM	Century Therapeutics to Present at the SITC 37th Annual Meeting (GlobeNewswire)
Oct-03-22 07:00AM	Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors (GlobeNewswire)
Sep-26-22 07:00AM	Century Therapeutics to Present at Chardans 6th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-06-22 07:00AM	Century Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-25-22 07:30AM	Century Therapeutics Receives Study May Proceed Notification from FDA for CNTY-101, the First Allogeneic Cell Therapy Product Candidate Engineered to Overcome Three Major Pathways of Host vs Graft Rejection (GlobeNewswire)
Aug-11-22 08:45AM	Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-07-22 01:43PM	Century Therapeutics nearly tripling planned space at One uCity Square (American City Business Journals)
Jul-01-22 09:18AM	Further weakness as Century Therapeutics (NASDAQ:IPSC) drops 13% this week, taking one-year losses to 71% (Simply Wall St.)
Jun-24-22 04:30PM	Century Therapeutics Announces Its Addition to the Russell Microcap® Index (GlobeNewswire) -6.39% -8.37%
Jun-21-22 04:30PM	Century Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium (GlobeNewswire) +5.60%
Jun-06-22 07:30AM	Century Therapeutics to Host Virtual Research and Development Day on June 13, 2022 (GlobeNewswire)
May-20-22 03:04PM	Pennsylvania Biotech Center's economic impact grows to $7B as it expands in Bucks County, report finds (American City Business Journals)
May-16-22 07:30AM	Century Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) +9.79%
May-03-22 04:30PM	Century Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-02-22 04:30PM	Century Therapeutics to Present at the ASGCT 25th Annual Meeting (GlobeNewswire)
Apr-18-22 04:30PM	Century Therapeutics to Present at the Chardan Genetic Medicines and Cell Therapy Manufacturing Summit (GlobeNewswire)
Apr-06-22 04:30PM	Century Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-23-22 04:30PM	Century Therapeutics to Present at the H.C. Wainwright Gene Therapy and Gene Editing Conference (GlobeNewswire) +5.97%
Mar-17-22 07:30AM	Century Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-09-22 04:05PM	Century Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire)
Jan-22-22 11:29AM	What's Behind Bristol Myers Squibb's Latest Partnership? (Motley Fool)
Jan-14-22 06:50AM	Inside the deal: Why Century Therapeutics picked Bristol Myers Squibb for its first Big Pharma mega-deal (American City Business Journals)
Jan-10-22 12:27PM	Century Therapeutics shares soar on potential multibillion-dollar deal with Bristol Myers Squibb (American City Business Journals) +14.52%
11:12AM	Century Therapeutics Rallies On Bristol Myers Squibb Strategic Collaboration (Investing.com)
08:08AM	Bristol Myers, Century Therapeutics Ink Pact For iPSC-Derived Allogeneic Cell Therapies (Benzinga)
06:59AM	Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies (GlobeNewswire)
Jan-04-22 04:30PM	Century Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.24%
Dec-17-21 07:00AM	Century Therapeutics Added to the NASDAQ Biotechnology Index (GlobeNewswire) +8.91%
Dec-16-21 06:30AM	Century Therapeutics Announces Presentation of Data at the 63rd American Society of Hematology Annual Meeting and Provides Pipeline Updates (GlobeNewswire)
Nov-22-21 08:00AM	Century Therapeutics to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference (GlobeNewswire) -17.56%
Nov-10-21 07:30AM	Century Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-04-21 09:00AM	Century Therapeutics to Present at the 63rd American Society of Hematology Annual Meeting and Host Virtual Research & Development Update (GlobeNewswire)
Oct-07-21 07:30AM	Century Therapeutics and Outpace Bio Enter Research Collaboration in CAR Engineering (GlobeNewswire)
Sep-17-21 04:01PM	Century Therapeutics Announces Its Addition to the Russell 2000® Index (GlobeNewswire) -15.35% -12.24%
Aug-12-21 08:00AM	Century Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates (GlobeNewswire)
Jun-22-21 04:01PM	Century Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It focuses on harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Quimi Daphne	Director	Sep 12 '24	Buy	1.53	5,000	7,657	5,000	Sep 16 04:18 PM
Farid Adrienne	Chief Operations Officer	Aug 05 '24	Sale	1.83	1,073	1,960	136,163	Aug 07 04:06 PM
Carr Douglas	SVP Finance & Operations	Aug 05 '24	Sale	1.83	289	528	334,041	Aug 07 04:06 PM
Farid Adrienne	Officer	Aug 05 '24	Proposed Sale	1.83	1,073	1,960		Aug 05 03:06 PM
Russotti Gregory	See Remarks	Jul 26 '24	Sale	2.50	586	1,465	274,933	Jul 31 09:08 AM
Russotti Gregory	Officer	Jul 26 '24	Proposed Sale	2.50	586	1,465		Jul 26 05:03 PM
Russotti Gregory	See Remarks	Jul 24 '24	Sale	2.52	1,600	4,029	275,519	Jul 25 05:04 PM
Russotti Gregory	See Remarks	Jul 23 '24	Sale	2.50	200	500	277,119	Jul 25 05:04 PM
Russotti Gregory	See Remarks	Jun 20 '24	Sale	2.84	5,000	14,178	277,319	Jun 24 04:49 PM
Russotti Gregory	See Remarks	Jun 05 '24	Sale	3.00	5,000	14,989	282,319	Jun 06 04:53 PM
Russotti Gregory	See Remarks	May 20 '24	Sale	3.00	5,000	14,978	287,319	May 21 04:09 PM
Russotti Gregory	See Remarks	May 06 '24	Sale	3.12	5,000	15,619	292,319	May 07 05:13 PM
Carr Douglas	SVP Finance & Operations	May 03 '24	Sale	3.11	257	798	317,323	May 07 05:13 PM
Farid Adrienne	Chief Operations Officer	May 03 '24	Sale	3.11	913	2,836	137,236	May 07 05:13 PM
Russotti Gregory	See Remarks	Apr 22 '24	Sale	3.10	5,000	15,490	297,319	Apr 24 04:17 PM
Farid Adrienne	Chief Operations Officer	Mar 06 '24	Option Exercise	1.03	30,684	31,605	144,833	Mar 08 06:29 PM
Farid Adrienne	Chief Operations Officer	Mar 07 '24	Option Exercise	1.03	22,831	23,516	136,980	Mar 08 06:29 PM
Farid Adrienne	Chief Operations Officer	Mar 06 '24	Sale	4.96	30,684	152,340	114,149	Mar 08 06:29 PM
Farid Adrienne	Chief Operations Officer	Mar 07 '24	Sale	5.14	22,831	117,342	114,149	Mar 08 06:29 PM
Farid Adrienne	Chief Operations Officer	Feb 16 '24	Option Exercise	1.03	485	500	114,634	Feb 21 04:10 PM
Farid Adrienne	Chief Operations Officer	Feb 16 '24	Sale	4.86	485	2,358	114,149	Feb 21 04:10 PM
Carr Douglas	SVP Finance & Operations	Feb 06 '24	Sale	4.49	557	2,499	303,580	Feb 07 05:21 PM
Carr Douglas	SVP Finance & Operations	Feb 05 '24	Sale	3.84	643	2,470	304,137	Feb 07 05:21 PM
Farid Adrienne	Chief Operations Officer	Feb 06 '24	Sale	4.49	1,784	8,005	114,149	Feb 07 05:21 PM
Farid Adrienne	Chief Operations Officer	Feb 05 '24	Sale	3.84	2,035	7,816	115,933	Feb 07 05:21 PM

Open in Screener

AMLX

Amylyx Pharmaceuticals Inc

Sep 20 • 04:00PM ET

3.10

Dollar change +0.22
Percentage change 7.64	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

AMLX Amylyx Pharmaceuticals Inc daily Stock Chart

Held by: VTI VB VXF IBB VBK SMLF SCHA FYC IWC VHT

Index	-	P/E	-	EPS (ttm)	-2.45	Insider Own	39.55%	Shs Outstand	67.71M	Perf Week	18.32%
Market Cap	211.05M	Forward P/E	-	EPS next Y	-1.75	Insider Trans	0.69%	Shs Float	41.15M	Perf Month	37.17%
Income	-165.87M	PEG	-	EPS next Q	-0.70	Inst Own	61.49%	Short Float	3.61%	Perf Quarter	74.16%
Sales	298.76M	P/S	0.71	EPS this Y	-623.81%	Inst Trans	32.34%	Short Ratio	0.92	Perf Half Y	8.01%
Book/sh	3.84	P/B	0.81	EPS next Y	52.14%	ROA	-42.22%	Short Interest	1.49M	Perf Year	-83.30%
Cash/sh	4.55	P/C	0.68	EPS next 5Y	-	ROE	-51.22%	52W Range	1.58 - 19.95	Perf YTD	-78.94%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-63.29%	52W High	-84.46%	Beta	-0.61
Dividend TTM	-	Quick Ratio	4.66	Sales past 5Y	2300.59%	Gross Margin	53.30%	52W Low	96.83%	ATR (14)	0.18
Dividend Ex-Date	Mar 28, 2018	Current Ratio	4.66	EPS Y/Y TTM	-100.06%	Oper. Margin	-51.85%	RSI (14)	76.58	Volatility	5.34% 5.95%
Employees	384	Debt/Eq	0.01	Sales Y/Y TTM	55.71%	Profit Margin	-55.52%	Recom	2.71	Target Price	4.25
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-439.59%	Payout	0.00%	Rel Volume	2.48	Prev Close	2.88
Sales Surprise	-109.59%	EPS Surprise	-46.58%	Sales Q/Q	-101.04%	Earnings	Aug 08 BMO	Avg Volume	1.62M	Price	3.10
SMA20	28.55%	SMA50	41.28%	SMA200	-52.89%	Trades		Volume	4,010,270	Change	7.64%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-18-24	Downgrade	Mizuho	Buy → Neutral	$32 → $4
Mar-11-24	Downgrade	Robert W. Baird	Outperform → Neutral	$37 → $4
Mar-11-24	Downgrade	Leerink Partners	Outperform → Market Perform	$27 → $4
Mar-08-24	Downgrade	Goldman	Buy → Neutral
Mar-08-24	Downgrade	Evercore ISI	Outperform → In-line
Jan-03-24	Initiated	Robert W. Baird	Outperform	$37
Dec-12-23	Initiated	Deutsche Bank	Buy	$36
Jul-24-23	Upgrade	Goldman	Neutral → Buy	$45 → $49
Mar-31-23	Initiated	Mizuho	Buy	$52
Jan-05-23	Initiated	BofA Securities	Buy	$50
May-25-22	Initiated	Citigroup	Buy	$21
Apr-01-22	Downgrade	Goldman	Buy → Neutral	$36 → $10

Show Previous Ratings

Sep-09-24 07:17PM	Director Karen Firestone Acquires 50,000 Shares of Amylyx Pharmaceuticals Inc (AMLX) (GuruFocus.com) +6.33% +5.56%
Sep-06-24 01:49AM	Director MILNE GEORGE M JR Acquires 100,000 Shares of Amylyx Pharmaceuticals Inc (AMLX) (GuruFocus.com) +7.73%
Aug-28-24 08:30AM	Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-12-24 09:00AM	Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer's Disease Pathology and Neurodegeneration (Business Wire)
Aug-08-24 07:00AM	Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results (Business Wire)
09:00AM	Loading…
Aug-05-24 09:00AM	Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024 (Business Wire)
04:32AM	EC grants orphan drug status for Amylyxs Wolfram treatment (Pharmaceutical Technology)
Aug-02-24 09:00AM	Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome (Business Wire)
Jul-10-24 10:53AM	Amylyx to rebuild pipeline with $35m Phase III ready GLP-1RA acquisition (Clinical Trials Arena) +25.45%
07:00AM	Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation (Business Wire)
03:00AM	Amylyx, with GLP-1 buy, doubles down on blood sugar drugs (BioPharma Dive)
Jul-09-24 04:01PM	Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide (Business Wire)
Jun-28-24 11:02AM	Amylyx ventures into metabolic diseases market with $35.1m deal (Pharmaceutical Technology)
Jun-04-24 09:00AM	Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-14-24 07:25AM	Mizuho Cuts Price Target on Amylyx Pharmaceuticals to $3 From $4, Keeps Neutral Rating (MT Newswires)
03:54PM	Loading…
May-10-24 03:54PM	Amylyx Pharmaceuticals Reports Q1 2024 Financial Results (GuruFocus.com) -7.14%
12:47PM	Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 08:15AM	Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results (Business Wire)
May-08-24 09:00AM	Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference (Business Wire)
May-02-24 09:00AM	Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024 (Business Wire)
Apr-30-24 12:02PM	Trials to watch: Four ALS drugs to keep an eye on (Clinical Trials Arena)
Apr-10-24 03:14PM	Amylyx Pharmaceuticals' Investigational Drug Shows Improved Pancreatic Function In Patients With Inherited Disorder (Benzinga) -7.87%
09:00AM	Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome (Business Wire)
Apr-08-24 09:00AM	Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024 (Business Wire)
Apr-04-24 01:20PM	Amylyx (AMLX) Withdraws ALS Drug, Cuts Workforce by 70% (Zacks)
10:05AM	ALS drug will be pulled from US market after study showed patients didn't benefit (Associated Press Finance)
07:52AM	UPDATE 1-Amylyx Pharma to remove ALS drug from US, Canada markets (Reuters)
07:43AM	Amylyx Is Cutting 70% of Its Workforce and Pulling ALS Drug From the Market (Barrons.com)
07:07AM	Amylyx Pharmaceuticals to remove ALS drug from US, Canada markets (Reuters)
07:00AM	Loading…
07:00AM	Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO/ALBRIOZA from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy (Business Wire)
06:09AM	Amylyx to pull ALS drug from market in rare move (BioPharma Dive)
Apr-03-24 05:45AM	Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX (PR Newswire)
Apr-01-24 07:30PM	Amylyx Pharmaceuticals Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information (GlobeNewswire)
Mar-27-24 07:36AM	European study finds popular ALS drug ineffective (BioPharma Dive) +5.11%
Mar-25-24 02:33PM	Investors Sue Amylyx Pharmaceuticals (AMLX) After Analyst Questions RELYVRIO Data Hagens Berman (GlobeNewswire)
Mar-14-24 06:49PM	3 Pharma Stocks to Sell in March Before They Crash & Burn (InvestorPlace) -7.85%
09:00AM	Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors (Business Wire)
Mar-13-24 10:00AM	SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx (PR Newswire)
09:03AM	Analysts on Wall Street Lower Ratings for These 10 Stocks (Insider Monkey)
Mar-12-24 07:55AM	After surprise trial failure, ALS doctors brace for one less treatment option (BioPharma Dive) -9.47%
Mar-11-24 12:34PM	Amylyx's (AMLX) ALS Drug Fails Pivotal Study, Stock Down 82% (Zacks) +13.10%
07:45AM	Amylyx CEOs look for a path forward following major setback (BioPharma Dive)
Mar-10-24 08:00AM	Wall Street Predicted a Blockbuster. Now the Drug May Be Withdrawn. (The Wall Street Journal)
Mar-08-24 06:27PM	Lost Money in Amylyx Pharmaceuticals, Inc.? Gibbs Law Group Investigates Potential Securities Law Violations (Business Wire) -82.29% +13.10%
04:05PM	Amylyx Stock Wipes Out Nearly All Of Its Value, Crashing 82%, After Pivotal ALS Drug Failure (Investor's Business Daily)
11:30AM	Maker of much-debated ALS drug says it may stop selling it after study showed it didn't work (Associated Press Finance)
10:20AM	Amylyxs ALS Drug Fails Trial, Raising Questions About Companys Future (Barrons.com)
10:12AM	Amylyx Stock Crashes 80% After Approved ALS Drug Fails Its Pivotal Test (Investor's Business Daily)
09:38AM	10 Biotech Stocks with Huge Potential (Insider Monkey)
09:26AM	Amylyx Pharmaceuticals Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information (GlobeNewswire)
07:07AM	Amylyx's ALS drug fails in late-stage confirmatory study (Reuters)
07:00AM	Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS (Business Wire)
02:05AM	Amylyx ALS drug fails crucial study, putting companys future in doubt (BioPharma Dive)
Feb-27-24 05:45AM	Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX (PR Newswire) +8.20%
Feb-26-24 11:39AM	AMLX NEWS: Johnson Fistel Encourages Amylyx Investors to Seek Counsel Before the Lead Plaintiff Deadline (GlobeNewswire)
Feb-25-24 06:30AM	7 Oversold Russell 2000 Stocks to Add to Your February Buy List (InvestorPlace)
Feb-23-24 04:05PM	Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
10:30AM	AMYLYX SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Amylyx To Contact Him Directly To Discuss Their Options (GlobeNewswire)
10:10AM	Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:00AM	AMLX Stockholders with Significant Losses Should Contact Robbins LLP for Information About Their Rights and Remedies Against Amylyx Pharmaceuticals, Inc. (Business Wire)
05:45AM	Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - AMLX (PR Newswire)
Feb-22-24 06:57PM	Investors Sue Amylyx Pharmaceuticals (AMLX) After Analyst Questions RELYVRIO Data Hagens Berman (GlobeNewswire) +21.10%
04:10PM	Amylyx Stock Rockets As ALS Drug Tacks On Another Triple-Digit Quarter (Investor's Business Daily)
08:15AM	Amylyx Pharmaceuticals, Inc. (AMLX) Misses Q4 Earnings Estimates (Zacks)
07:35AM	Amylyx Pharmaceuticals Inc (AMLX) Reports Robust Revenue Growth and Net Income for Full Year 2023 (GuruFocus.com)
07:00AM	Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-20-24 05:45AM	Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX (PR Newswire) -6.11%
Feb-19-24 12:40PM	Amylyx Pharmaceuticals (AMLX) Sued For Securities Fraud After Analyst Questions RELYVRIO Data Hagens Berman (GlobeNewswire)
Feb-15-24 04:05PM	Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024 (Business Wire)
02:13PM	Amylyx Pharmaceuticals (AMLX) Sued For Securities Fraud After Analyst Questions RELYVRIO Data Hagens Berman (GlobeNewswire)
09:00AM	Amylyx Pharmaceuticals to Present Updates on its AMX0114 and RELYVRIO Programs in ALS at the 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference (Business Wire)
Feb-13-24 09:16PM	Lost Money in Amylyx Pharmaceuticals, Inc.? Gibbs Law Group Investigates Potential Securities Law Violations (Business Wire) -7.94%
12:58PM	Get Rich Quick With These 3 Biotech Stocks to Buy Now (InvestorPlace)
Feb-12-24 08:09PM	Amylyx Pharmaceuticals (AMLX) Sued For Securities Fraud After Analyst Questions RELYVRIO Data Hagens Berman (GlobeNewswire)
11:09AM	Amylyx Pharmaceuticals Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information (GlobeNewswire)
Feb-08-24 09:00AM	Amylyx Pharmaceuticals Announces Completion of Enrollment in HELIOS, a Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome (Business Wire)
Jan-26-24 03:57PM	3 Biotech Stocks with Potential for Major Medical Breakthroughs in 2024 (InvestorPlace)
Jan-21-24 01:16PM	3 Top-Rated Biotech Stocks Wall Street Analysts Are Loving Now: January 2024 (InvestorPlace)
Jan-14-24 12:54PM	7 Healthcare Stocks Taking Medicine to the Next Level (InvestorPlace)
Jan-05-24 05:34AM	2 Biotech Stocks With Huge Catalysts in 2024 (Motley Fool)
Dec-26-23 07:02PM	5 Best IPO Stocks to Buy Heading into 2024 (Insider Monkey)
08:48AM	Is Amylyx (AMLX) Stock a Solid Choice Right Now? (Zacks)
Dec-22-23 09:00AM	Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy (PSP) (Business Wire)
Dec-11-23 08:36AM	Implied Volatility Surging for Amylyx (AMLX) Stock Options (Zacks)
Dec-04-23 09:00AM	Amylyx Pharmaceuticals Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS (Business Wire)
Nov-29-23 05:15PM	Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.19%
Nov-28-23 08:48AM	3 Top-Rated Biotech Stocks That Analysts Are Loving Now (InvestorPlace)
07:00AM	Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer (Business Wire)
Nov-27-23 09:00AM	RELYVRIO and AMX0114 Data to be Presented at 34th International Symposium on ALS/MND (Business Wire)
Nov-21-23 09:00AM	Amylyx Pharmaceuticals to Participate at the 6th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-12-23 11:59AM	Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 12:26AM	Q3 2023 Amylyx Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-09-23 05:04PM	Amylyx Crashes 32% On A Quarterly Report That Doesn't Bode Well For 2024 (Investor's Business Daily) -31.89%
12:12PM	Amylyx Crashes 27% As New ALS Drug Faces A Barrage Of Troubles (Investor's Business Daily)
08:05AM	Amylyx Pharmaceuticals Inc (AMLX) Reports Strong Q3 2023 Earnings with Significant Revenue Growth (GuruFocus.com)
07:00AM	Amylyx Pharmaceuticals Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-04-23 12:16PM	5 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds (Insider Monkey)
Nov-02-23 10:00AM	Amylyx Pharmaceuticals, Inc. (AMLX) Earnings Expected to Grow: What to Know Ahead of Q3 Release (Zacks) +5.38%
09:00AM	Amylyx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 9, 2023 (Business Wire)

Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cohen Joshua B	Co-Chief Executive Officer	Sep 12 '24	Option Exercise	1.57	34,449	54,085	3,237,301	Sep 16 05:39 PM
FRATES JAMES M	Chief Financial Officer	Sep 12 '24	Buy	2.53	40,000	101,368	233,464	Sep 16 05:30 PM
Firestone Karen	Director	Sep 05 '24	Buy	2.13	50,000	106,590	55,000	Sep 09 04:05 PM
MILNE GEORGE M JR	Director	Sep 03 '24	Buy	2.20	100,000	219,800	858,571	Sep 05 07:26 PM
Quimi Daphne	Director	May 14 '24	Buy	1.89	2,750	5,184	2,750	May 16 07:37 PM
Quimi Daphne	Director	May 15 '24	Buy	1.89	2,250	4,252	5,000	May 16 07:37 PM
Mazzariello Gina	Chief Legal Officer	May 15 '24	Sale	1.88	10,455	19,654	151,477	May 16 07:36 PM
Cohen Joshua B	Co-Chief Executive Officer	Mar 05 '24	Sale	18.73	4,135	77,440	3,023,002	Mar 07 04:05 PM
Klee Justin B.	Co-Chief Executive Officer	Mar 05 '24	Sale	18.73	4,135	77,440	2,959,308	Mar 07 04:05 PM
FRATES JAMES M	Chief Financial Officer	Mar 05 '24	Sale	18.73	1,792	33,560	134,784	Mar 07 04:05 PM
Mazzariello Gina	Chief Legal Officer	Mar 05 '24	Sale	18.73	1,540	28,841	81,372	Mar 07 04:05 PM
Mazzariello Gina	Chief Legal Officer	Feb 23 '24	Sale	18.76	2,838	53,231	46,245	Feb 27 05:59 PM
Klee Justin B.	Co-Chief Executive Officer	Jan 09 '24	Sale	16.33	5,841	95,372	2,836,776	Jan 11 05:11 PM
FRATES JAMES M	Chief Financial Officer	Jan 09 '24	Sale	16.33	2,716	44,347	112,035	Jan 11 05:11 PM
Cohen Joshua B	Co-Chief Executive Officer	Jan 09 '24	Sale	16.33	5,841	95,372	2,900,470	Jan 11 05:10 PM
Yeramian Patrick D	Chief Medical Officer	Jan 09 '24	Sale	16.33	2,812	45,915	205,605	Jan 11 05:04 PM
Olinger Margaret	Chief Commercial Officer	Dec 27 '23	Option Exercise	0.37	25,000	9,250	276,108	Dec 29 04:07 PM
Firestone Karen	Director	Dec 15 '23	Buy	14.97	4,000	59,880	5,000	Dec 19 04:37 PM
Cohen Joshua B	Co-Chief Executive Officer	Nov 16 '23	Option Exercise	1.57	63,694	100,000	2,906,311	Nov 20 08:20 PM

Open in Screener

FOLD

Amicus Therapeutics Inc

Sep 20 • 04:00PM ET

11.29

Dollar change +0.29
Percentage change 2.64	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

FOLD Amicus Therapeutics Inc daily Stock Chart

Held by: VTI VB IWM XBI VBK VXF IWO IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-0.40	Insider Own	2.55%	Shs Outstand	293.59M	Perf Week	-0.09%
Market Cap	3.35B	Forward P/E	59.03	EPS next Y	0.19	Insider Trans	-0.59%	Shs Float	289.03M	Perf Month	-6.62%
Income	-119.54M	PEG	-	EPS next Q	0.00	Inst Own	105.20%	Short Float	8.03%	Perf Quarter	11.89%
Sales	455.65M	P/S	7.35	EPS this Y	63.49%	Inst Trans	-4.40%	Short Ratio	8.92	Perf Half Y	-3.42%
Book/sh	0.45	P/B	25.25	EPS next Y	202.73%	ROA	-16.16%	Short Interest	23.20M	Perf Year	-8.21%
Cash/sh	0.88	P/C	12.88	EPS next 5Y	-	ROE	-97.94%	52W Range	9.02 - 14.57	Perf YTD	-20.44%
Dividend Est.	-	P/FCF	-	EPS past 5Y	22.84%	ROI	-21.03%	52W High	-22.51%	Beta	0.69
Dividend TTM	-	Quick Ratio	2.26	Sales past 5Y	37.81%	Gross Margin	87.96%	52W Low	25.17%	ATR (14)	0.35
Dividend Ex-Date	-	Current Ratio	2.75	EPS Y/Y TTM	37.86%	Oper. Margin	-5.58%	RSI (14)	51.25	Volatility	2.61% 2.71%
Employees	517	Debt/Eq	3.35	Sales Y/Y TTM	29.98%	Profit Margin	-26.23%	Recom	1.31	Target Price	17.25
Option/Short	Yes / Yes	LT Debt/Eq	3.29	EPS Q/Q	64.97%	Payout	-	Rel Volume	2.28	Prev Close	11.00
Sales Surprise	4.50%	EPS Surprise	8.93%	Sales Q/Q	34.04%	Earnings	Aug 08 BMO	Avg Volume	2.60M	Price	11.29
SMA20	-0.94%	SMA50	2.63%	SMA200	-1.24%	Trades		Volume	5,922,443	Change	2.64%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-06-24	Initiated	Jefferies	Buy	$18
May-30-24	Initiated	Wells Fargo	Overweight	$18
May-14-24	Upgrade	Guggenheim	Neutral → Buy	$13
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$15 → $20
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight	$14
Apr-13-22	Resumed	Goldman	Neutral	$11
Jan-14-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$12 → $16
Nov-15-21	Upgrade	Stifel	Hold → Buy	$12 → $16
Sep-30-21	Upgrade	JP Morgan	Neutral → Overweight	$16
Jul-19-21	Resumed	BTIG Research	Buy	$15
May-27-21	Initiated	Needham	Hold
May-21-21	Initiated	UBS	Buy	$16
Apr-14-21	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$17
Mar-02-21	Initiated	Stifel	Hold	$13
Feb-12-21	Downgrade	JP Morgan	Overweight → Neutral	$19
Feb-12-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$30 → $17
Dec-28-20	Resumed	Cantor Fitzgerald	Overweight	$20 → $30
Dec-10-20	Downgrade	Citigroup	Buy → Neutral	$20 → $27
Nov-11-20	Initiated	Berenberg	Hold
Jun-17-20	Initiated	BTIG Research	Buy	$19

Show Previous Ratings

Sep-03-24 07:46AM	UPDATE -- Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024 (GlobeNewswire)
07:05AM	Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024 (GlobeNewswire)
07:00AM	Amicus Therapeutics Announces Participation at the SSIEM 2024 Annual Symposium (GlobeNewswire)
Aug-30-24 07:00AM	Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024 (GlobeNewswire)
Aug-21-24 11:24AM	Amicus (FOLD) Banks on Galafold, High Dependence a Concern (Zacks)
10:31AM	Loading…
Aug-09-24 10:31AM	Amicus (FOLD) Up as Q2 Earnings & Sales Top, '24 View Updated (Zacks)
Aug-08-24 09:00PM	Amicus Therapeutics (FOLD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) +13.20%
08:25AM	Amicus Therapeutics (FOLD) Q2 Earnings and Revenues Top Estimates (Zacks)
07:22AM	Amicus Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Amicus Therapeutics Announces Second Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
Jul-30-24 07:00AM	Amicus Therapeutics to Announce Second Quarter 2024 Financial Results on August 8, 2024 (GlobeNewswire)
Jun-26-24 09:47AM	Do Options Traders Know Something About Amicus (FOLD) Stock We Don't? (Zacks)
Jun-05-24 07:00AM	Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
Jun-04-24 07:00AM	Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) as Best Pharmaceutical Product (GlobeNewswire)
May-24-24 08:30AM	Do Options Traders Know Something About Amicus (FOLD) Stock We Don't? (Zacks)
07:15AM	Loading…
May-14-24 07:15AM	Guggenheim Upgrades Amicus Therapeutics to Buy From Neutral With $13 Price Target (MT Newswires)
May-10-24 04:03PM	Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2024 Earnings Call Transcript (Insider Monkey)
01:10PM	Amicus Therapeutics Inc (FOLD) Q1 2024 Earnings: Surpasses Revenue Estimates and Projects ... (GuruFocus.com)
11:33AM	UBS Trims Price Target on Amicus Therapeutics to $19 From $20, Keeps Buy Rating (MT Newswires)
10:46AM	Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated (Zacks)
May-09-24 10:30PM	Amicus Therapeutics (FOLD) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks) -6.51%
11:56AM	FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:26AM	Amicus Therapeutics' Q1 Net Loss Narrows, Net Product Sales Rise (MT Newswires)
08:25AM	Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:21AM	Amicus Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
May-08-24 07:00AM	Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference (GlobeNewswire)
May-01-24 10:01AM	Will Amicus Therapeutics (FOLD) Report Negative Q1 Earnings? What You Should Know (Zacks)
07:00AM	Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024 (GlobeNewswire)
Mar-29-24 11:30AM	Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report? (Zacks)
09:53AM	Loading…
Mar-26-24 09:53AM	WuXi Biologics Reports Solid 2023 Annual Results (PR Newswire)
Mar-20-24 07:00AM	Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report (GlobeNewswire)
Mar-13-24 07:07AM	13 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Mar-06-24 11:56PM	Director Margaret Mcglynn Sells 15,000 Shares of Amicus Therapeutics Inc (FOLD) (GuruFocus.com) -5.62%
Mar-05-24 01:50PM	Amicus Therapeutics Stock Sees RS Rating Improve To 74 (Investor's Business Daily)
Mar-01-24 07:00AM	Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024 (GlobeNewswire)
Feb-29-24 11:25AM	Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2023 Earnings Call Transcript (Insider Monkey)
11:23AM	Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates (Zacks)
Feb-28-24 11:49PM	Q4 2023 Amicus Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -6.50%
08:20AM	Amicus Therapeutics (FOLD) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:32AM	Amicus Therapeutics Inc (FOLD) Reports 21% Revenue Growth in 2023, Eyes Non-GAAP Profitability ... (GuruFocus.com)
07:00AM	Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates (GlobeNewswire)
Feb-15-24 07:00AM	Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024 (GlobeNewswire) +6.22%
Feb-09-24 03:14PM	Amicus Therapeutics Stock Sees Improved Relative Strength Rating (Investor's Business Daily)
Feb-08-24 07:00AM	Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) at the 20th Annual WORLDSymposium (GlobeNewswire)
Feb-01-24 07:00AM	Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium 2024 (GlobeNewswire)
Jan-12-24 11:02PM	Amicus Therapeutics Inc Chief Accounting Officer Sells Company Shares (GuruFocus.com)
09:31AM	Amicus (FOLD) Stock Rises More Than 25% in 3 Months: Here's Why (Zacks)
Jan-08-24 09:40AM	Amicus (FOLD) Issues Preliminary Revenue Results for FY23 (Zacks)
Jan-07-24 04:00PM	Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook (GlobeNewswire)
Jan-05-24 07:02PM	Amicus Therapeutics Inc President and CEO Bradley Campbell Sells 15,833 Shares (GuruFocus.com)
Jan-03-24 11:46AM	15 Best Growth Stocks to Buy Under $25 (Insider Monkey)
07:00AM	Amicus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-30-23 09:01AM	Amicus Therapeutics Inc's Chief Development Officer Sells Shares (GuruFocus.com)
Dec-29-23 09:48AM	Amicus (FOLD) Banks on Galafold, Overdependence a Concern (Zacks)
07:01AM	Amicus Therapeutics Inc Chief Accounting Officer Sells Company Shares (GuruFocus.com)
Dec-24-23 06:17AM	Time to Pull the Trigger, Says Morgan Stanley About These 2 Healthcare Stocks (TipRanks)
Dec-21-23 05:01AM	Amicus Therapeutics Inc's Chief Development Officer Sells Shares (GuruFocus.com)
Dec-08-23 11:30AM	Why Is Amicus Therapeutics (FOLD) Up 15% Since Last Earnings Report? (Zacks)
Dec-05-23 06:38AM	BIO names longtime Amicus head John Crowley as new CEO (BioPharma Dive)
06:00AM	Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO (GlobeNewswire)
05:30AM	He Designed Drugs to Save His Children. Now Hes Working to Save Biotech, Too. (The Wall Street Journal)
Nov-15-23 09:48AM	7 Stocks Most Likely to Follow in WeWorks Woeful Footsteps (InvestorPlace)
Nov-10-23 10:07AM	Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 01:02PM	Amicus' (FOLD) Q3 Loss Narrows, Galafold Sales View Updated (Zacks) -12.19%
Nov-08-23 07:13AM	Amicus Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates (GlobeNewswire)
Nov-04-23 05:03AM	Insider Sell: Amicus Therapeutics Inc President and CEO Bradley Campbell Sells 11,700 Shares (GuruFocus.com)
Nov-02-23 10:00AM	Synlogic, Inc. (SYBX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Nov-01-23 10:01AM	Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
07:00AM	Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023 (GlobeNewswire)
Oct-27-23 07:00AM	Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023 (GlobeNewswire)
Oct-08-23 07:00AM	This Rare Disease Pharma Is a Hidden Gem (TheStreet.com)
Oct-05-23 07:45PM	Stay Invested Through the Uncertainty: J.P. Morgan Says Stocks Could Reach New Highs Next Year Here Are 2 Names to Pounce on Now (TipRanks)
03:01AM	Insider Sell: Amicus Therapeutics Inc President & CEO Bradley Campbell Sells 11,700 Shares (GuruFocus.com)
Oct-03-23 07:00AM	Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023 (GlobeNewswire)
Oct-02-23 08:20AM	Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration (GlobeNewswire) -9.29%
Oct-01-23 08:30PM	WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease (PR Newswire)
Sep-29-23 12:22PM	Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall, Friday, 9/29/2023 (Associated Press Finance)
09:09AM	Amicus (FOLD) Gets FDA Approval for Pompe Disease Drug (Zacks)
Sep-28-23 11:08AM	UPDATE 1-US FDA approves Amicus Therapeutics' muscle disorder treatment (Reuters) -7.92%
10:50AM	U.S. FDA approves Amicus Therapeutics' muscle disorder treatment (Reuters)
10:41AM	Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease (GlobeNewswire)
10:32AM	Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark (Investor's Business Daily)
Sep-21-23 08:42AM	Zacks.com featured highlights include Amicus Therapeutics, Genius Sports and Viad (Zacks)
Sep-07-23 11:30AM	Why Is Amicus Therapeutics (FOLD) Down 6.8% Since Last Earnings Report? (Zacks)
Sep-01-23 07:00AM	Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023 (GlobeNewswire)
Aug-29-23 07:00AM	Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023 (GlobeNewswire)
Aug-21-23 07:00AM	Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer (GlobeNewswire)
Aug-15-23 07:00AM	Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom (GlobeNewswire)
Aug-09-23 09:25AM	Amicus (FOLD) Misses on Q2 Earnings, Raises Revenue Guidance (Zacks)
Aug-08-23 08:40AM	Amicus Therapeutics (FOLD) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +10.53%
07:29AM	Amicus Therapeutics: Q2 Earnings Snapshot (AP Finance)
07:00AM	Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates (GlobeNewswire)
Aug-07-23 08:48AM	Why Earnings Season Could Be Great for Amicus Therapeutics (FOLD) (Zacks)
Aug-04-23 08:05AM	Zacks.com featured highlights include First Watch Restaurant Group, VersaBank and Amicus Therapeutics (Zacks)
Jul-31-23 07:00AM	Amicus Therapeutics to Announce Second Quarter 2023 Financial Results on August 8, 2023 (GlobeNewswire)
Jul-23-23 10:23AM	Amicus Therapeutics' (NASDAQ:FOLD) investors will be pleased with their favorable 33% return over the last year (Simply Wall St.)
Jul-20-23 02:24PM	Amicus Therapeutics Stock Scores Healthy Relative Strength Upgrade (Investor's Business Daily)
Jul-17-23 01:54PM	Amicus Therapeutics Stock Sees Improving Market Leadership; Earns 81 RS Rating (Investor's Business Daily)

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Campbell Bradley L	President and CEO	Sep 03 '24	Option Exercise	8.61	7,500	64,575	894,154	Sep 05 05:01 PM
Campbell Bradley L	President and CEO	Sep 03 '24	Sale	11.71	7,500	87,798	886,654	Sep 05 05:01 PM
BRADLEY CAMPBELL	Director	Sep 03 '24	Proposed Sale	11.61	7,500	87,075		Sep 03 04:19 PM
Campbell Bradley L	President and CEO	Aug 01 '24	Option Exercise	8.61	7,500	64,575	894,154	Aug 05 08:10 PM
Campbell Bradley L	President and CEO	Aug 01 '24	Sale	10.34	7,500	77,518	886,654	Aug 05 08:10 PM
BRADLEY CAMPBELL	Director	Aug 01 '24	Proposed Sale	10.31	7,500	77,325		Aug 01 04:25 PM
Campbell Bradley L	President and CEO	Jul 05 '24	Option Exercise	8.61	6,100	52,521	892,754	Jul 09 05:01 PM
Campbell Bradley L	President and CEO	Jul 05 '24	Sale	10.00	6,100	61,029	886,654	Jul 09 05:01 PM
Campbell Bradley L	President and CEO	Jul 01 '24	Option Exercise	8.61	1,400	12,054	888,054	Jul 03 04:22 PM
Campbell Bradley L	President and CEO	Jul 01 '24	Sale	10.00	1,400	14,003	886,654	Jul 03 04:22 PM
Campbell Bradley L	President and CEO	Jun 03 '24	Option Exercise	8.61	7,500	64,575	894,154	Jun 05 04:35 PM
Campbell Bradley L	President and CEO	Jun 03 '24	Sale	10.00	7,500	75,000	886,654	Jun 05 04:35 PM
Campbell Bradley L	President and CEO	May 01 '24	Option Exercise	8.61	7,500	64,575	894,154	May 03 05:21 PM
Campbell Bradley L	President and CEO	May 01 '24	Sale	10.07	7,500	75,524	886,654	May 03 05:21 PM
Campbell Bradley L	President and CEO	Apr 01 '24	Option Exercise	8.61	7,500	64,575	894,154	Apr 03 06:14 PM
Campbell Bradley L	President and CEO	Apr 01 '24	Sale	11.67	7,500	87,496	886,654	Apr 03 06:14 PM
SBLENDORIO GLENN	Director	Mar 07 '24	Option Exercise	2.80	15,000	42,000	83,596	Mar 11 05:36 PM
RAAB MICHAEL	Director	Mar 05 '24	Option Exercise	2.80	15,000	42,000	83,596	Mar 06 05:22 PM
MCGLYNN MARGARET G	Director	Mar 04 '24	Option Exercise	2.80	7,500	21,000	66,789	Mar 06 05:21 PM
MCGLYNN MARGARET G	Director	Mar 05 '24	Option Exercise	2.80	7,500	21,000	66,789	Mar 06 05:21 PM
MCGLYNN MARGARET G	Director	Mar 05 '24	Sale	13.40	7,500	100,500	59,289	Mar 06 05:21 PM
MCGLYNN MARGARET G	Director	Mar 04 '24	Sale	13.29	7,500	99,675	59,289	Mar 06 05:21 PM
Campbell Bradley L	President and CEO	Mar 01 '24	Option Exercise	10.54	15,833	166,904	887,052	Mar 05 05:14 PM
Campbell Bradley L	President and CEO	Mar 01 '24	Sale	13.14	15,833	208,017	871,219	Mar 05 05:14 PM
Crowley John F	Executive Chairman	Mar 01 '24	Sale	13.35	29,181	389,543	573,478	Mar 05 05:14 PM
Crowley John F	Executive Chairman	Feb 15 '24	Sale	13.81	31,614	436,551	697,628	Feb 20 05:23 PM
Campbell Bradley L	President and CEO	Feb 15 '24	Sale	14.00	4,167	58,338	871,219	Feb 20 05:21 PM
Clark David Michael	Chief People Officer	Feb 15 '24	Sale	14.00	4,427	61,978	253,664	Feb 20 05:20 PM
Rosenberg Ellen	Chief Legal Officer	Feb 07 '24	Option Exercise	5.16	29,600	152,736	397,254	Feb 08 04:40 PM
Rosenberg Ellen	Chief Legal Officer	Feb 06 '24	Option Exercise	5.16	400	2,064	368,054	Feb 08 04:40 PM
Rosenberg Ellen	Chief Legal Officer	Feb 07 '24	Sale	13.00	29,600	384,818	367,654	Feb 08 04:40 PM
Rosenberg Ellen	Chief Legal Officer	Feb 06 '24	Sale	13.00	400	5,200	367,654	Feb 08 04:40 PM
Campbell Bradley L	President and CEO	Feb 01 '24	Option Exercise	10.54	15,833	166,904	891,219	Feb 05 07:22 PM
Campbell Bradley L	President and CEO	Feb 01 '24	Sale	12.56	15,833	198,858	875,386	Feb 05 07:22 PM
Crowley John F	Executive Chairman	Feb 01 '24	Sale	12.62	31,614	398,918	750,838	Feb 05 07:22 PM
Crowley John F	Executive Chairman	Jan 22 '24	Sale	12.36	55,327	683,958	782,452	Jan 24 05:20 PM
Crowley John F	Executive Chairman	Jan 16 '24	Sale	12.78	31,614	404,106	837,779	Jan 18 05:09 PM
Crowley John F	Executive Chairman	Jan 10 '24	Sale	13.65	31,614	431,452	869,393	Jan 11 06:33 PM
Clark David Michael	Chief People Officer	Jan 08 '24	Sale	14.00	8,726	122,164	268,089	Jan 09 06:08 PM
Clark David Michael	Chief People Officer	Jan 09 '24	Sale	14.00	1,384	19,376	266,705	Jan 09 06:08 PM
Prout Samantha	Chief Accounting Officer	Jan 08 '24	Sale	14.00	30,767	430,827	82,290	Jan 09 06:07 PM
Prout Samantha	Chief Accounting Officer	Jan 09 '24	Sale	14.00	1,337	18,718	80,953	Jan 09 06:07 PM
Campbell Bradley L	President and CEO	Jan 02 '24	Option Exercise	10.54	15,833	166,904	956,138	Jan 04 06:35 PM
Campbell Bradley L	President and CEO	Jan 02 '24	Sale	14.23	15,833	225,380	947,805	Jan 04 06:35 PM
Rosenberg Ellen	Chief Legal Officer	Jan 02 '24	Option Exercise	5.16	30,000	154,800	372,285	Jan 04 06:24 PM
Rosenberg Ellen	Chief Legal Officer	Jan 02 '24	Sale	14.21	30,000	426,219	342,285	Jan 04 06:24 PM
Castelli Jeff	Chief Development Officer	Dec 28 '23	Sale	14.52	17,421	252,902	340,661	Dec 29 05:18 PM
Prout Samantha	Chief Accounting Officer	Dec 26 '23	Sale	14.00	7,659	107,228	121,912	Dec 28 05:09 PM
Rosenberg Ellen	Chief Legal Officer	Dec 26 '23	Option Exercise	5.16	30,000	154,800	372,285	Dec 28 05:08 PM
Rosenberg Ellen	Chief Legal Officer	Dec 27 '23	Option Exercise	5.16	5,000	25,800	347,285	Dec 28 05:08 PM
Rosenberg Ellen	Chief Legal Officer	Dec 26 '23	Sale	14.00	30,000	420,084	342,285	Dec 28 05:08 PM
Rosenberg Ellen	Chief Legal Officer	Dec 27 '23	Sale	14.07	5,000	70,327	342,285	Dec 28 05:08 PM
Castelli Jeff	Chief Development Officer	Dec 19 '23	Sale	13.25	17,500	231,875	359,736	Dec 20 04:41 PM
Castelli Jeff	Chief Development Officer	Dec 20 '23	Sale	13.10	1,654	21,667	358,082	Dec 20 04:41 PM
Crowley John F	Executive Chairman	Dec 15 '23	Sale	12.66	6,043	76,516	877,748	Dec 19 05:55 PM
Campbell Bradley L	President and CEO	Dec 01 '23	Option Exercise	2.94	11,702	34,404	803,863	Dec 05 05:07 PM
Campbell Bradley L	President and CEO	Dec 01 '23	Sale	11.08	11,702	129,693	792,161	Dec 05 05:07 PM
Crowley John F	Executive Chairman	Dec 01 '23	Sale	11.08	6,043	66,956	883,791	Dec 05 05:03 PM
Crowley John F	Executive Chairman	Nov 15 '23	Sale	10.84	6,043	65,497	889,834	Nov 17 05:23 PM
Campbell Bradley L	President and CEO	Nov 01 '23	Option Exercise	2.94	11,700	34,398	803,861	Nov 03 07:38 PM
Campbell Bradley L	President and CEO	Nov 01 '23	Sale	10.97	11,700	128,391	792,161	Nov 03 07:38 PM
Crowley John F	Executive Chairman	Nov 01 '23	Sale	10.97	6,044	66,327	895,877	Nov 03 07:37 PM
Crowley John F	Executive Chairman	Oct 16 '23	Sale	10.50	6,044	63,449	901,921	Oct 18 07:57 PM
Crowley John F	Executive Chairman	Oct 02 '23	Sale	11.25	6,044	67,967	907,965	Oct 04 06:58 PM
Campbell Bradley L	President & CEO	Oct 02 '23	Option Exercise	2.94	11,700	34,398	803,861	Oct 04 06:57 PM
Campbell Bradley L	President & CEO	Oct 02 '23	Sale	11.24	11,700	131,489	792,161	Oct 04 06:57 PM

IPSC

Century Therapeutics Inc

AMLX

Amylyx Pharmaceuticals Inc

FOLD

Amicus Therapeutics Inc

Upgrade your FINVIZ experience